Growth & profitability
- Revenue has declined 56.8% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
OVID Financials Ovid Therapeutics Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $7M | -$17M | 0.0% | -585.2% | -$38M | — | $13M |
| 2025 | $224M | — | 0.0% | 0.0% | — | — | $21M |
| 2024 | $566000 | -$26M | 0.0% | -10933.7% | -$56M | — | $26M |
| 2024 | $223M | — | 0.0% | 0.0% | — | — | $15M |
| 2024 | $223M | — | 0.0% | 0.0% | — | — | $30M |
| 2024 | $223M | — | 0.0% | 0.0% | — | — | $31M |
| 2023 | $392000 | -$52M | 0.0% | -15122.7% | -$46M | — | $27M |
| 2023 | $223M | — | 0.0% | 0.0% | — | — | $57M |
| 2023 | $223M | — | 0.0% | 0.0% | — | — | $72M |
| 2023 | $223M | — | 0.0% | 0.0% | — | — | $63M |
| 2022 | $2M | -$54M | 0.0% | -3696.4% | -$56M | — | $45M |
| 2021 | $208M | $123M | 0.0% | 59.6% | $118M | — | $188M |
| 2020 | — | -$81M | — | — | -$52M | — | $72M |
| 2019 | — | -$60M | — | — | -$51M | — | $42M |
| 2018 | — | -$52M | — | — | -$46M | — | $36M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$17M | — | — | — | — | $94M |
| Dec '25 | $718000 | $10M | 0.0% | -1712.1% | -$10M | — | $13M |
| Sep '25 | $132000 | -$12M | 0.0% | -9487.1% | -$13M | — | $21M |
| Jun '25 | $6M | -$5M | 0.0% | -80.9% | -$5M | — | $28M |
| Mar '25 | $130000 | -$10M | 0.0% | -9653.8% | -$10M | — | $21M |
| Dec '24 | $76000 | -$9M | 0.0% | -14107.9% | -$10M | — | $26M |
| Sep '24 | $173000 | -$14M | 0.0% | -7645.1% | -$15M | — | $15M |
| Jun '24 | $169000 | $9M | 0.0% | -12140.2% | -$14M | — | $30M |
| Mar '24 | $148000 | -$12M | 0.0% | -11768.2% | -$17M | — | $31M |
| Dec '23 | $142000 | -$15M | 0.0% | -12808.5% | -$12M | — | $27M |
| Sep '23 | $109000 | -$11M | 0.0% | -11035.8% | -$10M | — | $57M |
| Jun '23 | $75000 | -$12M | 0.0% | -18896.0% | -$12M | — | $72M |
| Mar '23 | $66000 | -$13M | 0.0% | -22563.6% | -$12M | — | $63M |
| Dec '22 | $46280 | -$12M | 0.0% | -26302.7% | -$9M | — | $45M |
| Sep '22 | $11102 | -$12M | 0.0% | -115329.3% | -$13M | — | $58M |
| Jun '22 | $0 | -$15M | — | — | -$14M | — | $73M |
| Mar '22 | $1M | -$16M | 0.0% | -1125.5% | -$20M | — | $167M |
| Dec '21 | — | -$26M | — | — | -$12M | — | $188M |
| Sep '21 | — | -$11M | — | — | -$11M | — | $202M |
| Jun '21 | — | -$16M | — | — | -$19M | — | $212M |
Valuation over time
How the market has priced OVID against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 2.2× (Mar '23) to 62.4× (Jun '26).
P/S
Frequently asked questions
Is OVID growing its revenue and profit?
Over the past 5 years, Ovid Therapeutics Inc.'s revenue has declined 56.8% per year. These are computed facts, not advice.
How much debt does OVID have?
As of FY2025, Ovid Therapeutics Inc. reported — of total debt against $13M of cash.
What is OVID's profit margin?
In FY2025, gross margin was —, operating margin -585.2%, and net margin -239.9%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.